Ocular Therapeutix公司 OCUL 深 沪
等待开盘 11-05 09:30:00 美东时间
7.14
+0.320
+4.69%
华盛通- 最 高7.165
- 今 开7.09
- 成交量 336.07万股
- 最 低 6.83
- 昨 收 6.82
- 总市值 15.68亿
- 52周最高 16.44
- 市盈率 静 --
- 换手率 1.53%
- 52周最低 6.00
- 委 比 45.74%
- 总股本 2.20亿
- 历史最高 44.19
- 量 比 1.45
- 振 幅 4.91%
- 历史最低 1.995
- 每 手 1
- 风险率 1.77%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅386.16%！摩根士丹利维持TeraWulf"超配"评级，上调目标价至65美元
今日重点评级关注：摩根士丹利：维持TeraWulf"超配"评级，目标价从62.5美元升至65美元；摩根士丹利：维持Hut 8"超配"评级，目标价从273美元升至275美元
10-13 12:30
UBS Initiates Coverage On Ocular Therapeutix with Buy Rating, Announces Price Target of $14
UBS analyst Alice Nettleton initiates coverage on Ocular Therapeutix (NASDAQ:OCUL) with a Buy rating and announces Price Target of $14.
10-12 21:20
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give...
10-06 18:23
美股大行评级 | 潜在涨幅11184.05%！如瑞迪博士获花旗上调目标价至1450美元，维持"买入"评级
今日重点评级关注：花旗：上调如瑞迪博士"买入"评级，目标价从1040美元升至1450美元；加拿大帝国商业银行：维持Inventiva"买入"评级，目标价从20美元升至21美元
09-30 08:33
Needham Reiterates Buy on Ocular Therapeutix, Maintains $18 Price Target
Needham analyst Serge Belanger reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy and maintains $18 price target.
09-29 17:46
美股大行评级 | 矿业股获齐声唱多！金田、纽曼矿业等目标价均获上调；携程遭看淡至60美元，较现价仍溢价5成
今日重点评级关注：Ascendiant Capital：维持Allarity Therapeutics"买入"评级，目标价从10.25美元升至11美元；Needham：上调Rocket Pharmaceuticals"买入"评级，目标价9美元
09-17 16:16
Ocular Therapeutix Announces Completion Of Pre-NDA Meeting With FDA For Investigational Product Candidate AXPAXLI For Treatment Of Wet Age-Related Macular Degeneration
Consistent with prior Type C Meeting, the Pre-NDA Meeting confirms Ocular’s plan to submit AXPAXLI NDA based on SOL-1 Week 52 efficacy and safety, interim SOL-R safety, and confirmatory evidence AXPAXLI NDA submission for wet AMD remains on track for 4Q 2026 NDA submission to include subjects that h...
09-15 19:05
Why Is Ocular Therapeutix Stock Gaining Monday?
Ocular Therapeutix Inc. (NASDAQ:OCUL) stock is trading higher on Monday as the stock reacts to underwhelming data from its rival, EyePoint Inc. (NASDAQ:EYPT). EyePoint released topline results from its pivotal Phase 3 LUGANO trial. The study evaluated Duravyu for wet age-related macular degeneration...
08-18 01:48
H World Group Posts Upbeat Q2 Results, Joins Almonty Industries, Diana Shipping And Other Big Stocks Moving Higher On Monday
U.S. stocks were lower, with the Dow Jones index falling over 100 points on Monday. Shares of H World Group Ltd (NASDAQ:HTHT) rose sharply after the company reported better-than-expected second-quarter financial results and raised its FY26 sales guidance. H World Group reported quarterly earnings of...
08-17 21:51
财报速睇 | Ocular Therapeutix公司 2026财年Q2营收0.13亿美元，同比增长0.1%；归母净利润亏损0.79亿美元，同比亏损扩大16.1%
华盛资讯8月4日讯，Ocular Therapeutix公司公布2026财年Q2业绩，公司Q2营收0.13亿美元，同比增长0.1%，归母净利润亏损0.79亿美元，同比亏损扩大16.1%。
08-04 01:40
